The latest news from academia, regulators
research labs and other things of interest
Posted: October 29, 2007
BioAlliance Pharma's New Entity, AMEP, Shows Anti-angiogenic And Antiproliferative Activity In Vitro And In Vivo
(Nanowerk News) BioAlliance Pharma SA (Euronext Paris - Code Isin: FR0010095596 -BIO), a specialty pharmaceutical company focused on the development and marketing of innovative therapeutics targeting cancer, HIV, opportunistic infections and drug resistance, today announced the first promising in vivo and in vitro results for its plasmid AMEP™. The anti-angiogenic and antiproliferative properties of this innovative product (BA 015 program) were presented at the 15th congress of the European Society of Gene and Cell Therapy (ESGCT), Rotterdam (Netherlands), October 27-30.
Alongside its drug delivery program, where it already has its first product on the market, BioAlliance Pharma has also invested in a program to identify and develop new therapeutic targets in the field of oncology, especially those involved in resistance and tumoral invasion. Its new drug candidate, AMEP™ or plasmid AMEP™, which codes for an anti-invasive peptide, is the first result of this program.
AMEP™ binds to cellular receptors, integrins, which are present on the endothelial cells of neovessels and on some tumoral cells. Its targets are two major integrins, anb3 (alpha-v-beta-3) and a5b1 (alpha-5-beta-1), involved in angiogenic and metastatic processes.
The in vitro research results presented at ESCGT show that AMEP™ inhibits both proliferation and invasion of endothelial cells that cause the formation of neovessels. It also inhibits the proliferation and migration of human melanoma cells.
The in vivo research results were achieved with the AMEP™ plasmid on an invasive melanoma model using intratumoral electrotransfer. The effect of a single dose gives more than 80 per cent inhibition of tumoral growth. With repeated doses, there is a 97 per cent inhibition of tumoral growth and in 40 per cent of cases complete and lasting (more than 80 days) regression of the tumors.
“These results are extremely promising for the treatment of invasive melanoma, which is today one of the more aggressive and difficult to treat cancers,” said Dominique Costantini, CEO at BioAlliance Pharma. “On the basis of these results, the product will now enter an active regulatory study phase prior to clinical trials during 2008.”
About BioAlliance Pharma
BioAlliance Pharma SA (Euronext Paris: BIO) is a specialty pharmaceutical company focused on the development and commercialization of innovative therapeutics targeting cancer, HIV, opportunistic infections and drug resistance.
The Company is currently conducting 3 phase III clinical trials on innovative products. Two products are based on the Lauriad® mucoadhesive technology, which allows an early and prolonged release of therapeutic agents at the site of the disease: one authorized product in France and two clinical international phase III trials ongoing (Loramyc® and acyclovir Lauriad®). One product is based on the Transdrug® nanoparticle technology designed specifically for intracellular targeting: one international phase III trial ongoing on primary liver cancer (doxorubicin Transdrug®). The company develops also a New Entities program focused on new targets in oncology and HIV.
The company concluded two strategic partnerships in 2007 to sell its Loramyc® product in Europe and in the US. BioAlliance Pharma has just announced the launch of Loramyc® on the French market.
This communication expressly or implicitly contains certain forward-looking statements concerning BioAlliance Pharma SA and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of BioAlliance Pharma SA to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. BioAlliance Pharma SA is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of BioAlliance Pharma SA to differ from those contained in the forward-looking statements please refer to the Risk Factors (Facteurs de Risque) section of the reference document approved by the AMF on 6 April 2007 under the number R. 07-031, which is available on the AMF website www.amf-france.org or BioAlliance Pharma S.A.'s website www.bioalliancepharma.com.